ICON Public (NASDAQ:ICLR) Price Target Cut to $265.00 by Analysts at JPMorgan Chase & Co.

ICON Public (NASDAQ:ICLR) had its target price decreased by JPMorgan Chase & Co. from $280.00 to $265.00 in a report released on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Several other equities research analysts also recently commented on the stock. Redburn Atlantic assumed coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price for the company. Barclays decreased their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Robert W. Baird lowered their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Finally, Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $285.75.

ICON Public Price Performance

Shares of ICLR opened at $195.51 on Monday. The business’s fifty day moving average is $208.91 and its 200 day moving average is $257.50. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market cap of $16.13 billion, a P/E ratio of 21.80, a P/E/G ratio of 1.79 and a beta of 1.20.

Hedge Funds Weigh In On ICON Public

Several institutional investors and hedge funds have recently bought and sold shares of ICLR. Kornitzer Capital Management Inc. KS grew its stake in shares of ICON Public by 40.6% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after acquiring an additional 28,050 shares during the period. Foyston Gordon & Payne Inc bought a new position in ICON Public during the third quarter worth about $11,672,000. Icon Wealth Advisors LLC increased its stake in shares of ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Entropy Technologies LP raised its position in shares of ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after purchasing an additional 5,095 shares during the period. Finally, Whittier Trust Co. lifted its stake in shares of ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after buying an additional 441 shares in the last quarter. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.